Tiny worms are reshaping how scientists search for brain disease treatments

A flatworm that lives in ponds and can regrow its own brain. A microscopic nematode whose entire nervous system has been mapped. These are not the creatures most people picture when they think of medical research — but scientists are increasingly putting them to work on some of the hardest problems in human neuroscience, from schizophrenia and drug addiction to neurodegenerative conditions.

Separately, a team at the University of Reading has been testing planaria — the pond-dwelling flatworms — as stand-ins for rodents in psychiatric drug research. When the researchers gave the worms haloperidol, a drug used to treat mental health conditions including schizophrenia, the worms became significantly less active, mirroring the response seen in mice and rats, according to the Independent.

This finding adds to growing evidence that tiny flatworms like planaria could play a valuable role in how we study the brain. They display certain responses to psychiatric drugs that resemble those seen in mammals, but using them involves far fewer ethical concerns.— Professor Vitaliy Khutoryanskiy, University of Reading

The stakes for animal welfare are real. According to UK government data cited by the Independent, 882,000 mice and 144,060 rats were used in animal research in 2023. A 2016 study found that rodent use in neuroscience had climbed from around 20 percent of all animal research in the 1980s to over 50 percent by the 2010s.

Close to a million mice and rats are used in UK research each year, but using planaria instead could potentially cut those numbers and still give us the answers we need to develop better treatments for people with serious mental health conditions. It's good for science and it's good for animal welfare.— Professor Vitaliy Khutoryanskiy, University of Reading

The Reading study is published in the journal Pharmaceutical Research. It builds on earlier planaria research into epilepsy treatments and drug addiction — the flatworms have previously been shown to exhibit signs of withdrawal symptoms, making them useful for studying dependency. A 2024 study cited by the Independent reported that one in 69 UK adults are using antipsychotic medication long-term, underlining the scale of need for better treatments.

Planaria belong to a family of flatworms with a notable biological quirk: some species were previously thought to be effectively 'immortal' due to their ability to regenerate lost body parts, including entire brains, according to the Independent. That regenerative capacity is part of what makes them tractable for neuroscience — researchers can observe how the animals recover and respond to chemical interventions.

C. elegans offers a different but complementary set of advantages. Its body is transparent, its lifespan is compressed, and its nervous system has been fully mapped — properties that allow scientists to watch neuronal changes unfold in real time, according to Nature Index. Transgenic lines of the worm have been engineered to express human disease-associated proteins including alpha-synuclein (linked to Parkinson's), tau (linked to Alzheimer's), and TDP-43 (linked to ALS), and the worms replicate hallmark features of each condition.

Recent C. elegans research highlighted by Nature Index has also shed light on how Parkinson's-linked proteins spread between cells. Studies in nematodes, cell cultures, and rodents found that certain genetic variants enhance the spread of protein aggregates via a specific molecular pathway, pointing toward kinase inhibition as a potential therapeutic strategy. Separately, work in worms carrying mutations in Parkinson's-linked genes PINK1 and PRKN found that a cellular stress response helped sustain dopaminergic neurons and delay behavioral decline — a finding that could inform treatments aimed at slowing neurodegeneration.

None of these research lines have yet produced approved human treatments, according to the multi-source summary. But the convergence of worm-based models across psychiatric conditions, rare childhood disorders, and age-related neurodegeneration suggests the field is moving from novelty to infrastructure — a shift that could reshape how early-stage drug candidates are identified and tested.

Why it matters — If worm-based models can reliably predict how psychiatric and neurological drugs work in humans, they could accelerate treatment development for conditions affecting millions while significantly reducing the use of rodents in research.

Reported by technology.org, independent.co.uk, nature.com